中国基金报记者 闻言 金通灵9月30日晚间发布公告称，公司犯欺诈发行证券罪，被判处罚金800万元；公司时任董事长、副董 事长兼总经理季伟犯违规披露重要信息罪、欺诈发行证券罪，被判有期徒刑6年，并处罚金300万元。 此前，江苏证监局已就金通灵2017年至2022年财务造假对金通灵及其相关责任人、年报审计机构作出行 政处罚。此外，金通灵特别代表人诉讼也已启动。 金通灵及其相关责任人遭遇上述连番处罚，成为监管部门对资本市场违法违规行为实施民事、行政、刑 事三位一体监管和处罚的最新案例，有助于提升资本市场违法犯罪行为的成本。 金通灵6名高管获刑 9月30日，金通灵收到的《刑事判决书》显示，上海市第三中级人民法院（以下简称法院）一审判决被 告单位金通灵犯欺诈发行证券罪，判处罚金800万元。 季伟犯违规披露重要信息罪，判处有期徒刑5年6个月，并处罚金300万元；犯欺诈发行证券罪，判处有 期徒刑2年。法院决定对季伟执行有期徒刑6年，并处罚金300万元。 金通灵时任财务总监、董事会秘书袁学礼，犯违规披露重要信息罪、欺诈发行证券罪，判处有期徒刑4 年8个月，并处罚金120万元。 金通灵总经理助理、时任董事许坤明，犯违规披露重要 ...

【导读】行政民事刑事立体化追责，金通灵案一审判原董事长获刑6年 中国基金报记者 闻言 金通灵9月30日晚间发布公告称，公司犯欺诈发行证券罪，被判处罚金800万元；公司时任董事长、副董 事长兼总经理季伟犯违规披露重要信息罪、欺诈发行证券罪，被判有期徒刑6年，并处罚金300万元。 此前，江苏证监局已就金通灵2017年至2022年财务造假对金通灵及其相关责任人、年报审计机构作出行 政处罚。此外，金通灵特别代表人诉讼也已启动。 金通灵及其相关责任人遭遇上述连番处罚，成为监管部门对资本市场违法违规行为实施民事、行政、刑 事三位一体监管和处罚的最新案例，有助于提升资本市场违法犯罪行为的成本。 金通灵6名高管获刑 9月30日，金通灵收到的《刑事判决书》显示，上海市第三中级人民法院（以下简称法院）一审判决被 告单位金通灵犯欺诈发行证券罪，判处罚金800万元。 季伟犯违规披露重要信息罪，判处有期徒刑5年6个月，并处罚金300万元；犯欺诈发行证券罪，判处有 期徒刑2年。法院决定对季伟执行有期徒刑6年，并处罚金300万元。 （原标题：财务造假！300091，原董事长获刑6年） 经查明，2017年至2022年，金通灵及其两家全资子公 ...

Group 1 - Company ST Qibu (603557.SH) was fined 10 million yuan for fraudulently issuing securities as per the verdict from the Lishui Intermediate People's Court on September 23 [2] - The China Securities Regulatory Commission (CSRC) imposed a total fine of 57 million yuan on ST Qibu for false records and significant omissions in its 2018, 2019 annual reports, and 2020 semi-annual report [3] - The Lishui City People's Procuratorate filed a public prosecution against ST Qibu on July 8, with the court hearing taking place on August 21 [3] Group 2 - The company acknowledged the first-instance judgment and stated that both the company and the defendants have the right to appeal, indicating uncertainty in the final judgment [3] - ST Qibu will continue to monitor the case and fulfill its information disclosure obligations [3]

每经记者｜许立波 每经编辑｜董兴生 思创医惠因欺诈发行证券，早前已于2024年1月被浙江证监局行政处罚，涉事人员被罚以重金并禁入市 场。然而，上述欺诈发行案并未随着浙江证监局采取的行政处罚而终结。 日前，思创医惠（300078.SZ，股价3.52元，市值39.35亿元）披露公告称，其收到杭州市公安局出具给 公司的《调取证据通知书》，杭州市公安局侦办的公司等涉嫌欺诈发行证券案需调取公司有关证据材 料。截至目前，上述案件尚处于公安机关侦查阶段，尚未有明确结论。 针对此事，8月19日，《每日经济新闻》记者独家联系到思创医惠前董事长章笠中，其正是此前欺诈发 行案中被监管部门点名处罚的核心人物。章笠中在回应记者提问时表示，此次公安机关介入调查，应该 与其当年任职期间的证券欺诈发行案件有关，但对于公安机关的调查是否涉及其个人层面，章笠中拒绝 进一步回应。同时，他确认自己目前已不在上市公司担任职务。 同日晚间，思创医惠董事会秘书也通过微信向记者回复称，目前上述案件还在调查阶段，公司在国资入 股后，治理与经营管理全面调整优化，经营情况稳定，资金充实，该调查目前对公司无重大影响。相关 责任人员早已不在公司任职，如涉及相关刑事责 ...

Core Viewpoint - The resignation of Vice President Hua Songyuan and ongoing investigations into alleged fraudulent securities issuance have negatively impacted the stock price and financial performance of Sichuang Medical Technology Co., Ltd. (思创医惠) [1][4] Group 1: Management Changes - Vice President Hua Songyuan resigned for personal career planning reasons and will no longer hold any position in the company after his resignation [1] - Hua's original term was set from December 6, 2024, to December 5, 2027 [1] Group 2: Financial Performance - Sichuang Medical has reported continuous net losses, with net profits of -878 million yuan in 2022, -874 million yuan in 2023, -502 million yuan in 2024, and -19.56 million yuan in the first quarter of 2025 [3] - The company has faced significant discrepancies in its financial disclosures, leading to regulatory scrutiny and penalties [2][4] Group 3: Legal Issues - The company is under investigation by the Hangzhou Public Security Bureau for alleged fraudulent securities issuance, with evidence being collected [1][4] - In January 2024, the company received administrative penalties from the China Securities Regulatory Commission for fabricating significant false content in public offering documents, resulting in inflated revenues and profits [4][5][6] - The company was fined 81.7 million yuan for the fraudulent activities, and its former chairman was banned from the market for 10 years [6] Group 4: Business Operations - Sichuang Medical operates in two main business segments: business intelligence and smart healthcare, providing IoT solutions for various industries [2] - The company has recently sold its 100% stake in a subsidiary, Medical Technology Co., Ltd., to alleviate financial burdens due to ongoing losses [6]

Core Viewpoint - The company Sichuan Medical Technology Co., Ltd. (思创医惠) is under criminal investigation for financial fraud related to previous fiscal years, following a notification from the Hangzhou Public Security Bureau [1][3][4]. Group 1: Investigation and Legal Actions - The investigation pertains to allegations of fraudulent issuance of securities, with the company required to provide relevant evidence [1][4]. - The investigation is a continuation of prior administrative penalties imposed by the Zhejiang Securities Regulatory Commission, which found the company had inflated revenues and profits through false business activities [5][6]. - The company has stated it will cooperate with the investigation and is currently in discussions regarding potential compensation for affected investors [7]. Group 2: Financial Performance and Adjustments - In 2024, the company reported revenues of approximately 690.77 million yuan, a decrease of 31.33% from the previous year, while the net loss attributable to shareholders was approximately 501.51 million yuan, a reduction in loss of 42.64% compared to 2023 [10][11]. - The company has undergone significant structural changes, including the resignation of its former chairman and a shift in control to new shareholders linked to the Cangnan County Finance Bureau [8][9]. - The company has divested its core business in smart healthcare, selling its subsidiary for 300 million yuan, and is now focusing on the Internet of Things (IoT) sector as part of its strategic pivot [9][10]. Group 3: Regulatory Environment - Recent trends indicate an increase in criminal accountability for financial fraud among listed companies, with regulatory bodies intensifying their oversight and enforcement actions [11].

Core Viewpoint - Sichuang Medical's involvement in financial fraud has led to criminal investigations, with the company cooperating with authorities during the ongoing inquiry [1][3][4]. Group 1: Investigation and Legal Actions - Sichuang Medical received a notice from Hangzhou Public Security Bureau regarding evidence collection for a fraud case related to securities issuance [1]. - The investigation focuses on past financial records and is linked to previous administrative penalties imposed by the Zhejiang Securities Regulatory Commission [3][4]. - The company was previously found to have inflated revenue and profits significantly, with a cumulative revenue inflation of 34.93 million yuan and profit inflation of 33.02 million yuan in 2019, representing 20.03% of total profit for that period [4][5]. Group 2: Financial Performance and Adjustments - In 2024, Sichuang Medical reported revenues of 690.77 million yuan, a decrease of 31.33% from the previous year, while the net loss was 501.51 million yuan, a reduction in losses by 42.64% compared to 2023 [9][10]. - The company has undergone significant restructuring, including the resignation of its former chairman and the sale of its subsidiary, which was the main platform for the fraudulent activities, for 300 million yuan [7][8]. - Following the divestment, the company aims to focus on the Internet of Things (IoT) business, shifting its growth strategy to "focus on IoT, reshape growth engines" [8]. Group 3: Regulatory Environment and Future Outlook - The recent increase in criminal accountability for financial fraud in the industry is highlighted by the Supreme Court and the China Securities Regulatory Commission's joint guidelines aimed at enhancing regulatory scrutiny and penalties for fraudulent activities [10]. - Sichuang Medical is actively engaging with investors regarding potential compensation plans and is committed to fulfilling its legal responsibilities [6].

Core Viewpoint - ST Qibu has been collectively sued, indicating serious issues that may lead to criminal penalties for key personnel involved in fraudulent activities [1][4][5] Group 1: Legal Issues - ST Qibu and six key personnel, including former executives, are facing criminal charges for securities fraud and failure to disclose important information [1][5] - The company has previously been penalized by the China Securities Regulatory Commission (CSRC) for information disclosure violations, resulting in a fine of 77 million yuan in December 2023 [1][8] - The allegations include financial fraud, with a total of 360 million yuan in inflated revenue and 129 million yuan in inflated profits over a two-and-a-half-year period [5][6] Group 2: Financial Performance - Since 2020, ST Qibu has reported continuous losses, with annual losses exceeding 100 million yuan [2][18] - The company expects to continue this trend, projecting a net loss of 30 to 45 million yuan for the first half of 2025 [2][18] - Cumulatively, losses since 2020 are estimated to reach 1.777 billion yuan if the upper limit of the 2025 projection is realized [18] Group 3: Corporate History and Background - ST Qibu, originally Zhejiang Qibu Children's Products Co., was listed in 2017 and was once known as the "first children's shoe stock" in A-shares [17] - The company initially performed well post-listing, with net profits of 194 million yuan, 181 million yuan, and 143 million yuan from 2017 to 2019 [18] - A strategic partnership with Xin Xuan Group aimed at transforming into live e-commerce did not yield expected results, leading to ongoing financial struggles [18]